Evec, bio-venture for development of antibody therapeutics
-
- Takada Kenzo
- Evec, Inc., Founder and Chairman, Representative director
Bibliographic Information
- Other Title
-
- 抗体ベンチャー（イーベック）
- コウタイ ベンチャー(イーベック)
Search this article
Abstract
Human blood B-lymphocytes are activated through natural immune reaction, such as reaction to infection. B-lymphocytes are stimulated repeatedly with a small amount of antigen, and thus only those producing high affinity antibodies are activated. Consequently the lymphocytes producing the antibodies with high-affinity are accumulated in human blood. Therefore, human lymphocytes are an excellent source of high-affinity antibodies. Evec, Inc. has established a unique method to develop high-affinity antibodies from human lymphocytes, using Epstein-Barr virus (EBV) which has the activity to induce proliferation of B-lymphocytes. The method is to induce proliferation of B-lymphocytes from human blood using EBV, and isolate those producing antibodies of interest. Here, I describe Exec's antibody technology and experiences of license negotiations with Mega Pharmas.
Journal
-
- Drug Delivery System
-
Drug Delivery System 27 (1), 40-46, 2012
THE JAPAN SOCIETY OF DRUG DELIVERY SYSTEM
- Tweet
Details 詳細情報について
-
- CRID
- 1390001204641347072
-
- NII Article ID
- 130002100431
- 40019180134
-
- NII Book ID
- AN10084591
-
- ISSN
- 18812732
- 09135006
-
- NDL BIB ID
- 023480025
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- NDL
- Crossref
- CiNii Articles
-
- Abstract License Flag
- Disallowed